Inhibikase Therapeutics Inc

NASDAQ:IKT  
0.94
+0.05 (+5.88%)
Earnings Announcements

Inhibikase Therapeutics Reports Full Year 2021 Financial Results

Published: 03/31/2022 21:08 GMT
Inhibikase Therapeutics Inc (IKT) - Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity.
Inhibikase Therapeutics - Expects Existing Cash and Cash Equivalents Sufficient to Fund Expenditure Requirements Into Q3 of 2023.
Revenue is expected to be $0.3 Million
Adjusted EPS is expected to be -$0.19

Next Quarter Revenue Guidance is expected to be $0.2 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.